SPDR S&P Pharmaceuticals ETF
XPH
XPH
79 hedge funds and large institutions have $172M invested in SPDR S&P Pharmaceuticals ETF in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
1% more funds holding
Funds holding: 78 → 79 (+1)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
Holders
79
Holding in Top 10
–
Calls
$852K
Puts
$7K
Top Buyers
| 1 | +$12.3M | |
| 2 | +$11.2M | |
| 3 | +$4.94M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.18M |
| 5 |
Citigroup
New York
|
+$2.33M |
Top Sellers
| 1 | -$8.21M | |
| 2 | -$8.1M | |
| 3 | -$6.76M | |
| 4 |
IAA
Ironsides Asset Advisors
Rocky Mount,
North Carolina
|
-$2.76M |
| 5 |
RCM
RNC Capital Management
Los Angeles,
California
|
-$1.83M |